A Phase I study of acivicin in refractory pediatric solid tumors

• DOI: 10.1007/bf00873802
• Publication Date: 2005-01-07T20:03:48Z
• Authors: Sylvain Baruchel; Mark Bernstein; V. Michael Whitehead; Susan Devine; Beverly Bell; Ronald Dubowy; Holcombe Grier; Cynthia Kretschmar; Anne-Marie Langevin; Teresa Vietti
• Keywords: 0301 basic medicine; Antimetabolites, Antineoplastic; Adolescent; Isoxazoles; gamma-Glutamyltransferase; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Drug Resistance, Neoplasm; Child, Preschool; Neoplasms; Injections, Intravenous; Tumor Cells, Cultured; Humans; Enzyme Inhibitors; Child

Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.